Latest news with #NasdaqCopenhagen
Yahoo
12-06-2025
- Health
- Yahoo
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,' said Martin Lange, executive vice president for Development at Novo Nordisk. 'We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.' Novo Nordisk is now planning to initiate a phase 3 development programme with amycretin for adults with overweight or obesity during the first quarter of 2026. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral Amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 Amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Company announcement No 17 / 2025 Attachment CA250612-amycretin-to-phase-3-clean
Yahoo
12-06-2025
- Health
- Yahoo
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,' said Martin Lange, executive vice president for Development at Novo Nordisk. 'We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.' Novo Nordisk is now planning to initiate a phase 3 development programme with amycretin for adults with overweight or obesity during the first quarter of 2026. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral Amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 Amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Company announcement No 17 / 2025 Attachment CA250612-amycretin-to-phase-3-cleanSign in to access your portfolio
Yahoo
10-06-2025
- Business
- Yahoo
Park Street A/S - total number of voting rights and capital resulting from the capital reduction
Park Street A/S Total number of voting rights and capital and changes in company's treasury shares Park Street A/S - total number of voting rights and capital resulting from the capital reduction With reference to the company announcement on 28 April 2025 regarding the general meeting's approval of a share capital reduction, Park Street A/S hereby announces that completion of the share capital reduction has been registered with the Danish Business Authority with effect on 10 June 2025. The cancellation of the 1,629,459 treasury A-shares (the listed shares) will be removed from trading on Nasdaq Copenhagen in the coming days. The total nominal value of the share capital reduction is DKK 13,794,324 corresponding to 1,629,459 A-shares (listed) and 12,164,865 B-shares (not listed). Accordingly, Park Street A/S' share capital is then reduced from DKK 57,175,572 to DKK 43,381,248. Consequently, Park Street A/S no longer holds any class A treasury shares nor any class B treasury shares. Prior to the share capital reduction, the treasury shares held by Park Street A/S corresponded to 24.13% of the company's total share capital. In accordance with section 31 of the Danish Capital Market Act, it is hereby announced that Park Street A/S, following registration of the share capital reduction, holds 0% of the total share capital. Finally, in accordance with section 32 of the Danish Capital Markets Act, Park Street A/S hereby announces that its share capital then amounts to a nominal value of DKK 43,381,248, corresponding to 43,381,248 shares of nominally DKK 1 each and a total of 43,381,248 voting rights. The share capital is divided into 11,198,178 class A shares and 32,183,070 class B shares of nominally DKK 1 each. For further information please contact Pradeep Pattem, CEO at parkstreet@ Company Website: Telephone Number: +45 33 33 93 03Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-06-2025
- Business
- Yahoo
Park Street A/S - total number of voting rights and capital resulting from the capital reduction
Park Street A/S Total number of voting rights and capital and changes in company's treasury shares Park Street A/S - total number of voting rights and capital resulting from the capital reduction With reference to the company announcement on 28 April 2025 regarding the general meeting's approval of a share capital reduction, Park Street A/S hereby announces that completion of the share capital reduction has been registered with the Danish Business Authority with effect on 10 June 2025. The cancellation of the 1,629,459 treasury A-shares (the listed shares) will be removed from trading on Nasdaq Copenhagen in the coming days. The total nominal value of the share capital reduction is DKK 13,794,324 corresponding to 1,629,459 A-shares (listed) and 12,164,865 B-shares (not listed). Accordingly, Park Street A/S' share capital is then reduced from DKK 57,175,572 to DKK 43,381,248. Consequently, Park Street A/S no longer holds any class A treasury shares nor any class B treasury shares. Prior to the share capital reduction, the treasury shares held by Park Street A/S corresponded to 24.13% of the company's total share capital. In accordance with section 31 of the Danish Capital Market Act, it is hereby announced that Park Street A/S, following registration of the share capital reduction, holds 0% of the total share capital. Finally, in accordance with section 32 of the Danish Capital Markets Act, Park Street A/S hereby announces that its share capital then amounts to a nominal value of DKK 43,381,248, corresponding to 43,381,248 shares of nominally DKK 1 each and a total of 43,381,248 voting rights. The share capital is divided into 11,198,178 class A shares and 32,183,070 class B shares of nominally DKK 1 each. For further information please contact Pradeep Pattem, CEO at parkstreet@ Company Website: Telephone Number: +45 33 33 93 03Sign in to access your portfolio
Yahoo
06-06-2025
- Business
- Yahoo
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ('Zealand Pharma') (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's incentive scheme. Each warrant gives the owner the right to subscribe for one newly issued Zealand Pharma share at a prespecified exercise price within the specific predefined time periods before expiration in the warrant programs. For a more detailed description of Zealand Pharma's warrant programs, see the company's Articles of Association, which are available on the website: The exercise price was DKK 224.40 per share for 4,163 of new shares and DKK 90.70 per share for 288,345 of new shares. The total proceeds to Zealand Pharma from the capital increase amount to DKK 27,087,068.70. The new shares give rights to dividends and other rights from the time of the respective warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma's general meetings. Zealand Pharma has only one class of shares. The new shares will be admitted to trading on Nasdaq Copenhagen after the capital increase has been registered with the Danish Business Authority. Following registration of the capital increase with the Danish Business Authority, the share capital of Zealand Pharma will be nominally DKK 71,343,804 divided into 71,343,804 shares with a nominal value of DKK 1 each and corresponding to a total of 71,343,804 votes. A full copy of the new and amended Articles of Association can be found at once registered with the Danish Business Authority. # # # About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharmaceutical companies as well as commercial partnerships for its marketed was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit ContactsAdam Lange (Investors)Vice President, Investor RelationsZealand PharmaEmail: alange@ Neshat Ahmadi (Investors)Investor Relations ManagerZealand PharmaEmail: neahmadi@ Anna Krassowska, PhD (Investors and Media)Vice President, Investor Relations & Corporate CommunicationsZealand Pharmaakrassowska@ in to access your portfolio
